Cargando…

Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19

INTRODUCTION: Although patients with severe COVID-19 are known to be at high risk of developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in-hospital mortality in critically ill patients remain poorly understood and controversial. The goal of this study was to inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoogenboom, Wouter S., Lu, Joyce Q., Musheyev, Benjamin, Borg, Lara, Janowicz, Rebeca, Pamlayne, Stacey, Hou, Wei, Duong, Tim Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769345/ https://www.ncbi.nlm.nih.gov/pubmed/35045130 http://dx.doi.org/10.1371/journal.pone.0262811

Ejemplares similares

Characterizing non-critically ill COVID-19 survivors with and without in-hospital rehabilitation
por: Musheyev, Benjamin, et al.
Publicado: (2021)

Longitudinal medical subspecialty follow-up of critically and non-critically ill hospitalized COVID-19 survivors up to 24 months after discharge
por: Musheyev, Benjamin, et al.
Publicado: (2023)

Functional status of mechanically ventilated COVID-19 survivors at ICU and hospital discharge
por: Musheyev, Benjamin, et al.
Publicado: (2021)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
por: Tacquard, Charles, et al.
Publicado: (2021)

Neural network analysis of clinical variables predicts escalated care in COVID-19 patients: a retrospective study
por: Lu, Joyce Q., et al.
Publicado: (2021)

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York
por: Hoogenboom, Wouter S., et al.
Publicado: (2021)

Brain MRI findings in severe COVID-19 patients: a meta-analysis
por: Boparai, Montek S., et al.
Publicado: (2023)

Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
por: Bonfim, Luana C.M.G., et al.
Publicado: (2023)

High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia
por: Nadeem, Rashid, et al.
Publicado: (2021)

COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
por: Paez Vargas, Juan José, et al.
Publicado: (2021)

Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
por: Diepstraten, Jeroen, et al.
Publicado: (2022)

Hospitalization, Critical Illness, and Mortality Outcomes of COVID‐19 in Patients With Rheumatoid Arthritis
por: Mehrotra‐Varma, Jai, et al.
Publicado: (2023)

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
por: Bikdeli, Behnood, et al.
Publicado: (2020)

Characteristics of COVID-19 patients with multiorgan injury across the pandemic in a large academic health system in the Bronx, New York
por: Lu, Justin Y., et al.
Publicado: (2023)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2021)

Prophylactic Anticoagulation in Nephrotic Syndrome
por: Gerstein, Jonathon, et al.
Publicado: (2023)

Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes
por: Al-Dorzi, Hasan M., et al.
Publicado: (2022)

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis
por: Hasan, Syed Shahzad, et al.
Publicado: (2020)

Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19
por: Lu, Joyce Q., et al.
Publicado: (2022)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
por: Poletto, Francesco, et al.
Publicado: (2022)

New‐onset and persistent neurological and psychiatric sequelae of COVID‐19 compared to influenza: A retrospective cohort study in a large New York City healthcare network
por: Iosifescu, Andrei L., et al.
Publicado: (2022)

Prophylactic use of laxative for constipation in critically ill patients
por: Masri, Y, et al.
Publicado: (2010)

Prophylactic use of laxative for constipation in critically ill patients
por: Masri, Yasser, et al.
Publicado: (2010)

Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database
por: Zou, Zhi-ye, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature
por: Hoogenboom, Wouter S., et al.
Publicado: (2022)

EVALUATION OF THERAPEUTIC VS PROPHYLACTIC ANTICOAGULATION IN NONCRITICALLY ILL PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA
por: GHOSH, KULDEEP, et al.
Publicado: (2022)

Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry
por: Grünewald, Martin, et al.
Publicado: (2021)

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis
por: Loffredo, Lorenzo, et al.
Publicado: (2022)

High-Dose Prophylactic Anticoagulation for COVID-19 Pneumonia: A Review of Benefits and Risks
por: Kattakola, Yeshu, et al.
Publicado: (2023)

The standard of care is standard for a reason: Commentary on “Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients: A systematic review and Meta-analysis of randomized clinical trials”
por: Milano, Victoria, et al.
Publicado: (2023)

Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid
por: Kuno, Toshiki, et al.
Publicado: (2021)

Outcomes of Hospitalized Patients With COVID-19 With Acute Kidney Injury and Acute Cardiac Injury
por: Lu, Justin Y., et al.
Publicado: (2022)

Prophylactic anticoagulation for patients in hospital with covid-19
Publicado: (2021)

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
por: Van Meerhaeghe, Tess, et al.
Publicado: (2022)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival
por: Kornberg, Arno, et al.
Publicado: (2020)

ANTICOAGULATION, BLEEDING, AND IMMUNOTHROMBOSIS IN CRITICALLY ILL PATIENTS WITH COVID-19
por: PAEZ VARGAS, JUAN, et al.
Publicado: (2021)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bc9vspa7lick8r54k89u7vi75e